Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aptiganel SCHEMBL30416816 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| Aptiganel SCHEMBL30481113 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| Aptiganel SCHEMBL151145 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| Aptiganel SCHEMBL7414862 | 0.99 | SIGMAR1 (1.00) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL6719553 | 0.86 | SIGMAR1 (1.00) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL6727461 | 0.84 | SIGMAR1 (0.73) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL6719522 | 0.84 | SIGMAR1 (1.00) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL16887967 | 0.83 | SIGMAR1 (0.71) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| Hydrochloric Acid SCHEMBL7412867 | 0.82 | SIGMAR1 (0.97) | SIGMAR1TP53CYP2D6TSHRTHPO | |
| SCHEMBL6728156 | 0.81 | SIGMAR1 (1.00) | SIGMAR1TP53CYP2D6TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | claimed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | claimed |
| CN-110831584-A | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2020-02-21 | — | — | CN | claimed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-20220296586-A1 | NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Vepachedu, Sreenivasarao (US) | 2022-09-22 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| CN-110831584-A | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2020-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | SIGMAR1 102/4885TP53 3271/4885CYP2D6 9/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | SIGMAR1 102/4885TP53 3271/4885CYP2D6 9/4885 |
| US-20220296586-A1 | NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | CYP2D6, HTR2A, CYP3A43 | SIGMAR1 203/4885TP53 2764/4885CYP2D6 1/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | SIGMAR1 94/4885TP53 3574/4885CYP2D6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.